Building connections: Neurotrophic factors in dementia
By Dr. Romi Fung, ND
By Dr. Romi Fung, ND
Dementia is an umbrella term that encompasses multiple neurodegenerative diseases resulting in cognitive symptoms. Characteristic to the symptom picture of dementia is not only classic memory impairments, but also includes language, problem-solving, executive functions, arithmetic and other cognitive and thinking capabilities. Therefore, dementia has a large impact on the individuals activities of daily living.
Alzheimer’s Disease, or Alzheimer’s Dementia (AD), is the most common cause of dementia, accounting for approximately 80% of dementia cases (Alzheimer’s Association, 2020). The other 20% of cases consists of Lewy Body Dementia, Vascular Dementia, Parkinson’s Dementia, Crutzfeldt-Jakob disease, Wernicke-Korsakoff syndrome, Frontotemporal Dementia and Mixed Dementia. These dementias all have differing etiologies that this article will not explore in depth.
The hallmark of the pathology of AD is the accumulation of beta-amyloid protein fragments that have aggregated outside neurons in the brain. Also of importance are tau tangles that are twisted in neurons and eventually lead to the death of neurons thereby affecting brain tissue. This pathological development occurs progressively over many years before symptoms emerge.
One of the concerns regarding the development of dementia is the ability to create new neural connections. Synaptogenesis is the creation of new synapses resulting in new connections between preexisting brain neurons. Brain neurons form synapses throughout the life span. This process is initiated by neuronal depolarization, however the numbers of synapses formed is dependent on the level of three key nutrients—uridine, the omega-3 fatty acid DHA, and choline (Wurtman, 2014).
Trophic factors for Alzheimer’s dementia
Trophic, as defined in the dictionary, is ‘of relating to nutrition; concerned in nutritive processes’ (Dictionary.com, 2021). Another definition by Merriam-Webster (2021) states that trophic factors “promot[e] cellular growth, differentiation, and survival.” In other words, nerve growth factor is a trophic agent. This part will explore some nutraceuticals as trophic factors.
One of the nutraceutical interventions to provide factors in building neural connections is vitamin D. Cross-sectional studies have consistently found that vitamin D levels are significantly low in individuals with AD and cognitive impairment compared to healthy adults. Longitudinal studies and meta-analysis have also exhibited an association of low vitamin D with cognitive impairment and Alzheimer’s disease (Sultan et al., 2020; Chai et al., 2019; Llewellyn et al., 2011)
In another study done by Chai et al. (2019), there are significant positive associations between deficient vitamin D (defined as <20 ng/mL) and risk of developing AD. By dividing subgroups in the deficient vitamin D to moderate deficiency (10-20 ng/mL) and severe deficiency (<10 ng/mL), there was a greater association with AD in the severe deficiency group in comparison to the moderate deficiency group (Chai et al., 2019). This indicates that the risk of AD was reduced with increased vitamin D levels.
It is observed that low vitamin D levels is associated with increased risk of AD. Vitamin D is suspected to be a potential modulator of neurogenesis. Vitamin D has been shown to regulate neurotrophic factors and influencing neuronal proliferation, differentiation, survival and growth (Groves & Burne, 2017). Low vitamin D levels, or hypovitaminosis D, in AD rat models increased the number of amyloid plaques (Morello et al., 2018).
Vitamin D is highly recommended to be tested before considering supplementation. At this time, there is no concrete evidence on an ideal level of serum vitamin D. However, a study done by Oudshoorn et al. (2008) suggests that there is a positive association between serum vitamin D levels and MMSE scores, with participants with serum vitamin D higher than 50nmol/L generally scoring the highest. In regards to dosing, in a double-blind randomized controlled trial of postmenopausal women with levels than 30ng/mL by Castle et al. (2020), women who took 2000IU daily found to perform better in learning and memory tests compared to the 600IU and 4000IU groups.
Another intervention in supporting neurogenesis is magnesium. Magnesium affects many biochemical mechanisms vital for neuronal properties and synaptic plasticity, including the response of N-methyl D-aspartate (NMDA) receptors to excitatory amino acids, stability and viscosity of the cell membrane, and antagonism of calcium (Li et al., 2014).
Magnesium is arguably often overlooked however it is cornerstone to our health. Magnesium levels were found to be decreased in various tissues of AD patients and negatively correlated with clinical deterioration (Li et al., 2014). Moreover, Magnesium was demonstrated to modulate the trafficking and processing of amyloid-ß precursor protein in transgenic mice (Li et al., 2014).
Magnesium supplementation comes in many forms. One form that is more appropriate in managing cognitive decline is magnesium threonate. Magnesium threonate treatment was shown to reduce Aß-plaque, prevented synapse loss and memory decline in the transgenic mice (Li et al., 2014). Strikingly, magnesium threonate treatment was effective even when the treatment was given to the mice at the end-stage of their Alzheimer’s disease-like pathological progression (Li et al., 2014).
Magnesium itself has a poor penetration across the blood brain barrier (Vink, 2016). However, magnesium threonate is a more permeable magnesium salt and is a preferred option in neurological conditions (Vink, 2016).
Phosphatidylcholine and Citocholine
Choline is a major constituent of all biological membranes including neurons and glial cells (Blusztain et al., 1990). Brain sample studies dating to the 1980s and 1990s showed reduced levels of phosphatidylcholine and phosphatidylethanolamine and increased levels of their metabolites, glycerophosphocholine and glycerophosphoethanolamine, respectively, in the cerebral cortex of AD patients as compared to age-matched controls and to patients with Down syndrome, Parkinson’s disease and Huntington’s disease (Blusztain et al., 1990).
Citocholine is another treatment option. Citicoline exhibits neuroregenerative effects and activates neurogenesis, synaptogenesis, and angiogenesis and enhances neurotransmitter metabolism (Martynov & Gusev, 2015). In the IDEALE study testing for effectiveness and safety of citocholine by Cotroneo et al. (2013), 1000mg of citocholine was administered to 349 patients with mild cognitive impairment. Results found that there were positive results in the treated group in comparison to the control group based on MMSE scores 9 months into the study (Cotroneo et al., 2013).
DHA is a component of omega-3 fatty acid which is found in fish oils and plays a role in neuron development. DHA supplementation significantly promotes neurite growth, synaptogenesis, and increases the levels of pre- and post-synaptic proteins involved in synaptic transmission and LTP thereby improving synaptic function (Cao et al., 2009). A double-blind, randomized controlled trial by Yurko-Mauro et al. (2010) showed that in 485 subjects, those supplemented with 900mg daily of DHA had improved learning and memory function.
Besides relying on nutraceutical interventions, there are lifestyle habits that are foundational to our cognitive health. Ideally, these are considerations that need to be made alongside or prior to nutraceutical interventions. These lifestyle changes influence a major neurotrophin.
One of the most extensively studied neurotrophins is Brain-derived neurotrophic factor (BDNF). In general, the functions of BDNF are related to control of development of neuronal and glial cells, as well as activity-dependent regulation of the synaptic structure and its maintenance, which are critical for memory and cognition (Kowianski et al., 2018). In other words, BDNF has a central role in brain plasticity (Hakansson et al., 2017).
There are many ways to upregulate BDNF. Basic activities include physical activity and sleep.
Physical activity has been shown to affect BDNF levels. A study done by Hakansson et al. (2017) found that even a single 35-minute session of physical exercise had a larger impact on serum BDNF than cognitive training or mindfulness practice. Physical activity is probably the biggest proponent to cognitive health and cannot be stressed enough!
Sleep also has a significant contribution to BDNF. Chronic sleep deprivation has been found to be associated with downregulation of hippocampal BDNF (Rahmani et al., 2019). In reading this, there may be some memories of those days back in studying in medical school; these nights of deprived sleep affected our ability to encode memory for regurgitating in exams, especially with long term memory. In a study done by Fan et al. (2019), participants with short sleep duration (defined as less than six hours) had decreased BDNF levels compared with the healthy controls who slept greater than six hours. There is definitely a need to work with the foundations of health including optimizing sleep to improve cognition and BDNF levels.
Although these are interventions that show evidence that there are benefits to addressing cognitive decline, the primary care practitioner must first conduct a thorough assessment of the patient. Understanding which cognitive domain is affected can provide better insight on which parts of the brain are affected and if it truly is cognitive impairment (eg. Focus, concentration and working memory and the frontal lobe can also be misinterpreted as dementia).
In addition to neurotrophic factors, there is a need to understand that for any chronic condition there are two sides of the condition. In this case, fortifying synaptogenesis through trophic factors and supplementation is one approach, but only if underlying processes that impede the neuronal health have been addressed. A holistic, functional approach in addressing cognitive decline is warranted; factors that contribute to the expression of B-secretase in creating insoluble amyloid plaque needs to be addressed such as chronic inflammation, dysglycemia and hyperinsulinemia, toxins and heavy metals, cardiovascular health and anemia can impede on the proper functioning of the brain. By only primarily supplementing patients with trophic agents only depicts one part of the picture; without addressing the factors that impede on brain health, we are not taking a holistic, functional approach in optimizing cognitive health.
Alzheimer’s Association. (2020). 2020 Alzheimer’s disease facts and figures. Retrieved from: https://doi.org/10.1002/alz.12068
Cao, D., Kevala, K., Kim, J., Moon, H. S., Jun, S. B., Lovinger, D., & Kim, H. Y. (2009). Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. Journal of neurochemistry, 111(2), 510–521. https://doi.org/10.1111/j.1471-4159.2009.06335.x
Castle, M., Fiedler, N., Pop, L. C., Schneider, S. J., Schlussel, Y., Sukumar, D., Hao, L., & Shapses, S. A. (2020). Three Doses of Vitamin D and Cognitive Outcomes in Older Women: A Double-Blind Randomized Controlled Trial. The journals of gerontology. Series A, Biological sciences and medical sciences, 75(5), 835–842. https://doi.org/10.1093/gerona/glz041
Chai, B., Gao, F., Wu, R. et al. Vitamin D deficiency as a risk factor for dementia and Alzheimer’s disease: an updated meta-analysis. BMC Neurol 19, 284 (2019). https://doi.org/10.1186/s12883-019-1500-6
Cotroneo, A. M., Castagna, A., Putignano, S., Lacava, R., Fantò, F., Monteleone, F., Rocca, F., Malara, A., & Gareri, P. (2013). Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clinical interventions in aging, 8, 131–137. https://doi.org/10.2147/CIA.S38420
Dictionary.com. (2021). -trophic. https://www.merriam-webster.com/dictionary/trophic
Groves, N. J., & Burne, T. (2017). The impact of vitamin D deficiency on neurogenesis in the adult brain. Neural regeneration research, 12(3), 393–394. https://doi.org/10.4103/1673-5374.202936
Håkansson, K., Ledreux, A., Daffner, K., Terjestam, Y., Bergman, P., Carlsson, R., Kivipelto, M., Winblad, B., Granholm, A. C., & Mohammed, A. K. (2017). BDNF Responses in Healthy Older Persons to 35 Minutes of Physical Exercise, Cognitive Training, and Mindfulness: Associations with Working Memory Function. Journal of Alzheimer’s disease : JAD, 55(2), 645–657. https://doi.org/10.3233/JAD-160593
Kowiański, P., Lietzau, G., Czuba, E., Waśkow, M., Steliga, A., & Moryś, J. (2018). BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cellular and molecular neurobiology, 38(3), 579–593. https://doi.org/10.1007/s10571-017-0510-4
Li, W., Yu, J., Liu, Y., Huang, X., Abumaria, N., Zhu, Y., Huang, X., Xiong, W., Ren, C., Liu, X. G., Chui, D., & Liu, G. (2014). Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Molecular brain, 7, 65. https://doi.org/10.1186/s13041-014-0065-y
Llewellyn, D. J., Lang, I. A., Langa, K. M., & Melzer, D. (2011). Vitamin D and cognitive impairment in the elderly U.S. population. The journals of gerontology. Series A, Biological sciences and medical sciences, 66(1), 59–65. https://doi.org/10.1093/gerona/glq185
Martynov, M. Y., & Gusev, E. I. (2015). Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. Journal of experimental pharmacology, 7, 17–28. https://doi.org/10.2147/JEP.S63544
Merriam-Webster. (2021). Trophic. https://www.merriam-webster.com/dictionary/trophic
Morello, M., Landel, V., Lacassagne, E., Baranger, K., Annweiler, C., Féron, F., & Millet, P. (2018). Vitamin D Improves Neurogenesis and Cognition in a Mouse Model of Alzheimer’s Disease. Molecular neurobiology, 55(8), 6463–6479. https://doi.org/10.1007/s12035-017-0839-1
Oudshoorn, C., Mattace-Raso, F. U., van der Velde, N., Colin, E. M., & van der Cammen, T. J. (2008). Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer’s disease. Dementia and geriatric cognitive disorders, 25(6), 539–543.
Rahmani, M., Rahmani, F., & Rezaei, N. (2020). The Brain-Derived Neurotrophic Factor: Missing Link Between Sleep Deprivation, Insomnia, and Depression. Neurochemical research, 45(2), 221–231. https://doi.org/10.1007/s11064-019-02914-1
Sultan, S., Taimuri, U., Basnan, S. A., Ai-Orabi, W. K., Awadallah, A., Almowald, F., & Hazazi, A. (2020). Low Vitamin D and Its Association with Cognitive Impairment and Dementia. Journal of aging research, 2020, 6097820. https://doi.org/10.1155/2020/6097820
Vink R. (2016). Magnesium in the CNS: recent advances and developments. Magnesium research, 29(3), 95–101. https://doi.org/10.1684/mrh.2016.0408
Wurtman R. J. (2014). A nutrient combination that can affect synapse formation. Nutrients, 6(4), 1701–1710. https://doi.org/10.3390/nu6041701
Yurko-Mauro, K., McCarthy, D., Rom, D., Nelson, E. B., Ryan, A. S., Blackwell, A., Salem, N., Jr, Stedman, M., & MIDAS Investigators (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer’s & dementia : the journal of the Alzheimer’s Association, 6(6), 456–464. https://doi.org/10.1016/j.jalz.2010.01.013
Dr. Romi Fung is a Naturopathic Physician practicing in Richmond, British Columbia, Canada. A recent graduate from the Canadian College of Naturopathic Medicine, Romi helps patients living with dementia improve their quality of life by taking an integrative and functional approach. On top of his practice, Romi is currently pursuing doctoral studies in Aging and Health at Queen’s University and is an Adjunct Clinical Faculty at the Boucher Institute of Naturopathic Medicine. www.DrRomiFungND.com.